This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Non-invasive brain stimulation improves object-location learning in the elderly
Flöel, Agnes,
Suttorp, Wiebke,
Kohl, Oliver,
Kürten, Julia,
Lohmann, Hubertus,
Breitenstein, Caterina,
Knecht, Stefan
Remembering the location of objects, an integral part of everyday life, is known to decline with advancing age and early in the course of neurodegenerative dementia. Here, we aimed to test if object-location learning and its retention could be modified by noninvasive brain stimulation. In a group of 20 elderly (mean age 62.1 years) right-handed […]
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Dockens, Randy,
Wang, Jun-Sheng,
Castaneda, Lorna,
Sverdlov, Oleksandr,
Huang, Shu-Pang,
Slemmon, Randy,
Gu, Huidong,
Wong, Oi,
Li, Hewei,
Berman, Robert M.,
Smith, Christina,
Albright, Charles F.,
Tong, Gary
Background and Objectives: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women […]
Role of a multidisciplinary program in improving outcomes in cognitively impaired heart failure older patients
Del Sindaco, Donatella,
Pulignano, Giovanni,
Di Lenarda, Andrea,
Tarantini, Luigi,
Cioffi, Giovanni,
Tolone, Stefano,
Tinti, Maria Denitza,
Monzo, Luca,
Barbati, Giulia,
Minardi, Giovanni
Background: Cognitive impairment (CI) frequently complicates Heart failure (HF) and is associated with increased mortality and morbidity. Previous studies reported that nurse-lead home-based multidisciplinary program (MP) may not improve the prognosis of this high-risk group. In the present study, we analysed the relative effectiveness of an integrated hospital-based MP in patients with cognitive impairment.; Methods: […]
Detecting MCI and dementia in primary care: effectiveness of the MMS, the FAQ and the IQCODE corrected
Cruz-Orduña, Isabel,
Bellón, José M.,
Torrero, Pedro,
Aparicio, Esperanza,
Sanz, Ana,
Mula, Nieves,
Marzana, Garbiñe,
Begué, Concepción,
Cabezón, Dionisio,
Olazarán, Javier
Objectives: To study the yield of three instruments for detection of patients with cognitive impairment in primary care. To investigate whether combining tests is better for detecting impairment than applying them separately.; Methods: Seven primary care physicians (PCP) systematically recruited individuals aged over 49 years with a complaint or suspicion of cognitive impairment. The tests […]
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study
Carlsson, Cynthia M.,
Xu, Guofan,
Wen, Zhifei,
Barnet, Jodi H.,
Blazel, Hanna M.,
Chappell, Richard J.,
Stein, James H.,
Asthana, Sanjay,
Sager, Mark A.,
Alsop, David C.,
Rowley, Howard A.,
Fain, Sean B.,
Johnson, Sterling C.
Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic […]
Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease
Burstein, Aaron H,
Zhao, Qinying,
Ross, Joel,
Styren, Scot,
Landen, Jaren W.,
Ma, Wendy W.,
McCush, Fred,
Alvey, Christine,
Kupiec, James W.,
Bednar, Martin M.
Objective: Ponezumab (PF-04360365) is a humanized anti-amyloid beta (Aβ) monoclonal antibody designed for treatment of Alzheimer disease (AD). A single 2-hour intravenous infusion of 0.1 to 10 mg/kg was previously shown to be safe and well tolerated in subjects with mild to moderate AD, with measurable effects on plasma and cerebrospinal fluid Aβ. This phase […]